A host-guest complex formed by CD modified hyaluronic acid (HA-CD) and Ad modified hyaluronic acid (HA-Ad) was prepared to co-deliver anti-TGF-β and anti-inflammatory cytokine interleukin-10 (IL-10) to treat chronic kidney disease (CDK) for localized immunotherapy to avoid renal fibrosis [103]. Here, IL10 is linked to chronic kidney disease.